Suzhou NG Biomedicine

Suzhou NG Biomedicine is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative antibody-based therapeutics. The company focuses on oncology and autoimmune diseases, leveraging its proprietary antibody engineering platforms to create next-generation biologics, including bispecific antibodies and optimized monoclonal antibodies. Their lead programs target well-validated pathways such as PD-1/PD-L1 and CTLA-4, aiming to improve efficacy and safety profiles compared to existing treatments. Suzhou NG Biomedicine operates primarily out of the Suzhou Biobay industrial park, a major hub for life sciences innovation in China.